111 related articles for article (PubMed ID: 10740639)
1. [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Sasaki K; Yanagida T; Ohya M; Ishikawa H
Gan To Kagaku Ryoho; 2000 Mar; 27(3):443-9. PubMed ID: 10740639
[TBL] [Abstract][Full Text] [Related]
2. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Ishida T; Kusaba T; Hayakawa H
Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
[TBL] [Abstract][Full Text] [Related]
3. [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Miyamoto Y; Yagi K; Teramachi M; Oomasa M; Tomiyama K
Gan To Kagaku Ryoho; 1999 Jan; 26(1):125-30. PubMed ID: 9987508
[TBL] [Abstract][Full Text] [Related]
4. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Shinohara H; Yonekawa H; Machimura T; Furukawa T; Nishihori H; Kurihara N; Urakami H; Nemoto Y
Gan To Kagaku Ryoho; 1998 Feb; 25(3):397-402. PubMed ID: 9492834
[TBL] [Abstract][Full Text] [Related]
6. [Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Miyashita M; Onda M; Ikeda K; Bando K; Hagiwara N; Tsuchiya Y; Yoshiyuki T; Kiyama T; Saito T; Sasajima K; Yamashita K
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1629-35. PubMed ID: 10553422
[TBL] [Abstract][Full Text] [Related]
7. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Tanimura S; Banba J; Tomoyasu H; Masaki M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
9. [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1347-57. PubMed ID: 1386976
[TBL] [Abstract][Full Text] [Related]
10. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
[TBL] [Abstract][Full Text] [Related]
11. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
Eguchi F; Taguchi T; Furue H; Ikeda M; Tsukakoshi S;
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1423-9. PubMed ID: 11681251
[TBL] [Abstract][Full Text] [Related]
12. [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1891-903. PubMed ID: 1387775
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of granisetron hydrochloride for nausea and vomiting induced by oral anticancer drugs].
Togo S; Kunisaki C; Moriwaki Y; Yamaguchi S; Ichikawa Y; Oki S; Shimada H; Takahashi M; Ike H; Fukushima T; Obi Y; Kubo A; Takahashi T; Hosoi H; Fukazawa S; Suda T; Yamazaki Y
Gan To Kagaku Ryoho; 2000 Jul; 27(7):1021-8. PubMed ID: 10925688
[TBL] [Abstract][Full Text] [Related]
14. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
Horichi N; Taguchi T; Furue H; Ikeda M; Tsukakoshi S
Gan To Kagaku Ryoho; 2001 Jul; 28(7):953-60. PubMed ID: 11478144
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Hardy J; Daly S; McQuade B; Albertsson M; Chimontsi-Kypriou V; Stathopoulos P; Curtis P
Support Care Cancer; 2002 Apr; 10(3):231-6. PubMed ID: 11904788
[TBL] [Abstract][Full Text] [Related]
16. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
17. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
19. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
[TBL] [Abstract][Full Text] [Related]
20. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
